Schrodinger (SDGR) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Schrodinger (SDGR) has outperformed Vera Therapeutics (VERA) over the past year, gaining 35.4% versus a loss of 1.8%. Over five years, VERA leads with a +101.5% price change compared with -50.7% for SDGR. Vera Therapeutics is the larger company by market cap ($2.18 billion vs $2.04 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDGR | VERA |
|---|---|---|
| Share price | $27.29 | $30.25 |
| Market cap | $2.04B | $2.18B |
| 1-day change | -5.57% | +2.82% |
| YTD return | +52.63% | -40.26% |
| 1-year return | +35.37% | -1.79% |
| 5-year return | -50.70% | +101.53% |
| EPS (TTM) | $-0.74 | $-5.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.78 | $56.05 |
| 52-week low | $10.95 | $23.05 |
| Distance from 52-week high | -19.21% | -46.03% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -21.47% | +156.20% |
| Average volume | 1.69M | 2.24M |
| Shares outstanding | 65.64M | 72.06M |
| Employees | 850 | 361 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SDGR has outperformed VERA by 37.2 percentage points over the past year.
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 361 employees
SDGR vs VERA FAQ
Which is bigger, Schrodinger or Vera Therapeutics?
Vera Therapeutics (VERA) is larger, with a market capitalization of $2.18B compared with $2.04B for Schrodinger (SDGR).
Which stock has performed better over the past year, SDGR or VERA?
SDGR returned +35.37% over the past 12 months, compared with -1.79% for VERA (price return, excluding dividends). Past performance does not predict future results.
Are Schrodinger and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.